Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;101:2678-2681

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goette, A.
Right arrow Articles by Lendeckel, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goette, A.
Right arrow Articles by Lendeckel, U.
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Arrythmias-basic studies

(Circulation. 2000;101:2678.)
© 2000 American Heart Association, Inc.


Brief Rapid Communications

Regulation of Angiotensin II Receptor Subtypes During Atrial Fibrillation in Humans

Andreas Goette, MD; Marco Arndt, PhD; Christoph Röcken, MD; Antje Spiess, BSc; Thorsten Staack, MS; J. Christoph Geller, MD; Christof Huth, MD; Siegfried Ansorge, PhD; Helmut U. Klein, MD; Uwe Lendeckel, PhD

From University Hospital Magdeburg, Division of Cardiology (A.G., T.S., J.C.G., H.U.K), Institute of Immunology (M.A., A.S.), Institute of Pathology (C.R.), Department of Cardiovascular Surgery (C.H.), and Institute of Experimental Internal Medicine (S.A., U.L.), Magdeburg, Germany.

Correspondence to Andreas Goette, MD, University Hospital Magdeburg, Division of Cardiology, Leipziger Str 44, 39120 Magdeburg, Germany. E-mail andreas.goette{at}medizin.uni-madgeburg.de

Background—Previous studies have suggested that atrial fibrillation (AF) is associated with the activation of the atrial angiotensin system. However, it is not known whether the expression of angiotensin II receptors changes during AF. The purpose of this study was to determine the atrial expression of angiotensin II type 1 and type 2 receptors (AT1-R and AT2-R) in patients with AF.

Methods and Results—Atrial tissue samples from 30 patients undergoing open heart surgery were examined. Eleven patients had chronic persistent AF (>=6 months; cAF), 8 patients had paroxysmal AF (pAF), and 11 patients were in sinus rhythm. AT1-R and AT2-R were localized in the atrial tissue by immunohistochemistry and quantified at the protein and mRNA level by Western blotting and quantitative polymerase chain reaction. Both types of AT-R were predominantly expressed in atrial myocytes in all groups. The amount of AT1-R was reduced to 34.9% during cAF (P<0.01) and to 51.7% during pAF (P<0.05) compared with patients in sinus rhythm. In contrast, AT2-R was increased during cAF (246%; P=NS) and pAF (505%; P<0.01). AT1-R/AT2-R mRNA content was similar in all groups.

Conclusions—AF is associated with the down-regulation of atrial AT1-R and the up-regulation of AT2-R proteins. These findings may help define the pathophysiological role of the angiotensin system in the structural remodeling of the fibrillating atria.


Key Words: angiotensin • atrium • fibrillation • receptors • remodeling




This article has been cited by other articles:


Home page
Therapeutic Advances in Cardiovascular DiseaseHome page
J. L. Serra and M. Bendersky
Review: Atrial fibrillation and renin-angiotensin system
Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 215 - 223.
[Abstract] [PDF]


Home page
Exp. Biol. Med.Home page
A. Bukowska, L. Schild, G. Keilhoff, D. Hirte, M. Neumann, A. Gardemann, K. H. Neumann, F.-W. Rohl, C. Huth, A. Goette, et al.
Mitochondrial Dysfunction and Redox Signaling in Atrial Tachyarrhythmia
Experimental Biology and Medicine, May 1, 2008; 233(5): 558 - 574.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
D. N. Tziakas, G. K. Chalikias, N. Papanas, D. A. Stakos, S. V. Chatzikyriakou, and E. Maltezos
Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation
Europace, August 1, 2007; 9(8): 589 - 596.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Shiroshita-Takeshita, B. J.J.M. Brundel, B. Burstein, T.-K. Leung, H. Mitamura, S. Ogawa, and S. Nattel
Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure
Cardiovasc Res, April 1, 2007; 74(1): 75 - 84.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 651 - 745.
[Full Text] [PDF]


Home page
Eur Heart JHome page
N. Dagres, G. Karatasakis, F. Panou, G. Athanassopoulos, T. Maounis, E. Tsougos, K. Kourea, I. Malakos, D. Th. Kremastinos, and D. V. Cokkinos
Pre-treatment with Irbesartan attenuates left atrial stunning after electrical cardioversion of atrial fibrillation
Eur. Heart J., September 1, 2006; 27(17): 2062 - 2068.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Osranek, K. Fatema, F. Qaddoura, A. Al-Saileek, M. E. Barnes, K. R. Bailey, B. J. Gersh, T. S.M. Tsang, K. J. Zehr, and J. B. Seward
Left Atrial Volume Predicts the Risk of Atrial Fibrillation After Cardiac Surgery: A Prospective Study
J. Am. Coll. Cardiol., August 15, 2006; 48(4): 779 - 786.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation, August 15, 2006; 114(7): e257 - e354.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Y. Yin, D. Dalal, Z. Liu, J. Wu, D. Liu, X. Lan, Y. Dai, L. Su, Z. Ling, Q. She, et al.
Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation
Eur. Heart J., August 1, 2006; 27(15): 1841 - 1846.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
M. Paul, A. Poyan Mehr, and R. Kreutz
Physiology of local Renin-Angiotensin systems.
Physiol Rev, July 1, 2006; 86(3): 747 - 803.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. R. Ehrlich, S. H. Hohnloser, and S. Nattel
Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence
Eur. Heart J., March 1, 2006; 27(5): 512 - 518.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. Milliez, N. DeAngelis, C. Rucker-Martin, A. Leenhardt, E. Vicaut, E. Robidel, P. Beaufils, C. Delcayre, and S. N. Hatem
Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction
Eur. Heart J., October 2, 2005; 26(20): 2193 - 2199.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
W. Anne, R. Willems, T. Roskams, P. Sergeant, P. Herijgers, P. Holemans, H. Ector, and H. Heidbuchel
Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation
Cardiovasc Res, September 1, 2005; 67(4): 655 - 666.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. C. Dudley Jr, N. E. Hoch, L. A. McCann, C. Honeycutt, L. Diamandopoulos, T. Fukai, D. G. Harrison, S. I. Dikalov, and J. Langberg
Atrial Fibrillation Increases Production of Superoxide by the Left Atrium and Left Atrial Appendage: Role of the NADPH and Xanthine Oxidases
Circulation, August 30, 2005; 112(9): 1266 - 1273.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
P. Ellinghaus, R. J. Scheubel, D. Dobrev, U. Ravens, J. Holtz, J. Huetter, U. Nielsch, and H. Morawietz
Comparing the global mRNA expression profile of human atrial and ventricular myocardium with high-density oligonucleotide arrays
J. Thorac. Cardiovasc. Surg., June 1, 2005; 129(6): 1383 - 1390.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. G. Bourassa
Angiotensin II inhibition and prevention of atrial fibrillation and stroke
J. Am. Coll. Cardiol., March 1, 2005; 45(5): 720 - 721.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. M. Kistler, N. C. Davidson, P. Sanders, S. P. Fynn, I. H. Stevenson, S. J. Spence, J. K. Vohra, P. B. Sparks, and J. M. Kalman
Absence of acute effects of angiotensin II on atrial electrophysiology in humans
J. Am. Coll. Cardiol., January 4, 2005; 45(1): 154 - 156.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
N. Hanna, S. Cardin, T.-K. Leung, and S. Nattel
Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure
Cardiovasc Res, August 1, 2004; 63(2): 236 - 244.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. L. L'Allier, A. Ducharme, P.-F. Keller, H. Yu, M.-C. Guertin, and J.-C. Tardif
Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation
J. Am. Coll. Cardiol., July 7, 2004; 44(1): 159 - 164.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Goette and U. Lendeckel
Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease
J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2363 - 2363.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Boldt, J. Garbade, J. F. Gummert, and S. Dhein
Reply
J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2363 - 2364.
[Full Text] [PDF]


Home page
JAMAHome page
J. P. Mathew, M. L. Fontes, I. C. Tudor, J. Ramsay, P. Duke, C. D. Mazer, P. G. Barash, P. H. Hsu, and D. T. Mangano
A Multicenter Risk Index for Atrial Fibrillation After Cardiac Surgery
JAMA, April 14, 2004; 291(14): 1720 - 1729.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. Wasson, H. K. Reddy, and M. L. Dohrmann
Current Perspectives of Electrical Remodeling and Its Therapeutic Implications
Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 129 - 144.
[Abstract] [PDF]


Home page
HeartHome page
A Boldt, U Wetzel, J Lauschke, J Weigl, J Gummert, G Hindricks, H Kottkamp, and S Dhein
Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease
Heart, April 1, 2004; 90(4): 400 - 405.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. Caballero, R. Gomez, I. Moreno, L. Nunez, T. Gonzalez, C. Arias, M. Guizy, C. Valenzuela, J. Tamargo, and E. Delpon
Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current
Cardiovasc Res, April 1, 2004; 62(1): 86 - 95.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Xu, G. Cui, F. Esmailian, M. Plunkett, D. Marelli, A. Ardehali, J. Odim, H. Laks, and L. Sen
Atrial Extracellular Matrix Remodeling and the Maintenance of Atrial Fibrillation
Circulation, January 27, 2004; 109(3): 363 - 368.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K.-C. Ueng, T.-P. Tsai, W.-C. Yu, C.-F. Tsai, M.-C. Lin, K.-C. Chan, C.-Y. Chen, D.-J. Wu, C.-S. Lin, and S.-A. Chen
Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation: Results of a prospective and controlled study
Eur. Heart J., December 1, 2003; 24(23): 2090 - 2098.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Boldt, U. Wetzel, J. Weigl, J. Garbade, J. Lauschke, G. Hindricks, H. Kottkamp, J. F. Gummert, and S. Dhein
Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease
J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1785 - 1792.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Cardin, D. Li, N. Thorin-Trescases, T.-K. Leung, E. Thorin, and S. Nattel
Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways
Cardiovasc Res, November 1, 2003; 60(2): 315 - 325.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
C. Boixel, V. Fontaine, C. Rucker-Martin, P. Milliez, L. Louedec, J.-B. Michel, M.-P. Jacob, and S. N. Hatem
Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat
J. Am. Coll. Cardiol., July 16, 2003; 42(2): 336 - 344.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
K. Kumagai, H. Nakashima, H. Urata, N. Gondo, K. Arakawa, and K. Saku
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2197 - 2204.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. U. Klein and A. Goette
Blockade of atrial angiotensin II type 1 receptors: A novel antiarrhythmic strategy to prevent atrial fibrillation?
J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2205 - 2206.
[Full Text] [PDF]


Home page
CirculationHome page
E. Vermes, J.-C. Tardif, M. G. Bourassa, N. Racine, S. Levesque, M. White, P. G. Guerra, and A. Ducharme
Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction: Insight From the Studies Of Left Ventricular Dysfunction (SOLVD) Trials
Circulation, June 17, 2003; 107(23): 2926 - 2931.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
I. Savelieva and A. John Camm
Atrial fibrillation and heart failure: natural history and pharmacological treatment
Europace, January 1, 2003; 5(s1): S5 - S19.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Goette, U. Lendeckel, and H. U Klein
Signal transduction systems and atrial fibrillation
Cardiovasc Res, May 1, 2002; 54(2): 247 - 258.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. J.J.M. Brundel, R. H. Henning, H. H. Kampinga, I. C. Van Gelder, and H. J.G.M. Crijns
Molecular mechanisms of remodeling in human atrial fibrillation
Cardiovasc Res, May 1, 2002; 54(2): 315 - 324.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Nattel
Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?
Cardiovasc Res, May 1, 2002; 54(2): 347 - 360.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
B. J.J.M Brundel, J. Ausma, I. C van Gelder, J. J.L Van Der Want, W. H van Gilst, H. J.G.M Crijns, and R. H Henning
Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation
Cardiovasc Res, May 1, 2002; 54(2): 380 - 389.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. Shinagawa, H. Mitamura, S. Ogawa, and S. Nattel
Effects of inhibiting Na+/H+-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling
Cardiovasc Res, May 1, 2002; 54(2): 438 - 446.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
Y. Shi, D. Li, J.-C. Tardif, and S. Nattel
Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure
Cardiovasc Res, May 1, 2002; 54(2): 456 - 461.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Li, K. Shinagawa, L. Pang, T. K. Leung, S. Cardin, Z. Wang, and S. Nattel
Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing-Induced Congestive Heart Failure
Circulation, November 20, 2001; 104(21): 2608 - 2614.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Arndt, U. Lendeckel, C. Rocken, K. Nepple, C. Wolke, A. Spiess, C. Huth, S. Ansorge, H. U. Klein, and A. Goette
Altered Expression of ADAMs (A Disintegrin And Metalloproteinase) in Fibrillating Human Atria
Circulation, February 12, 2002; 105(6): 720 - 725.
[Abstract] [Full Text] [PDF]